SEC Form 5 · accession 0000899243-19-003326
Crinetics Pharmaceuticals, Inc. · CRNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Marc Wilson
Officer — See Remarks
Period of report
Dec 31, 2018
Accepted (ET)
Feb 12, 2019 · 5:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001658247
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Nov 20, 2018 | J | 1,470 | $14.45 | A | 57,321 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c).
- F2Includes 55,851 shares of restricted stock issued upon the Reporting Person's early exercise of a stock option that remain unvested. 25% of the restricted shares vested on January 4, 2019, and 1/48th of the total remaining number of restricted shares will vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
Remarks
Chief Financial Officer and Secretary Exhibit 24 - Power of Attorney